Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Prostate Cancer

  Free Subscription


08.04.2019

1 Am J Pathol
2 BJU Int
1 BMC Cancer
1 Cancer
2 Cancer Lett
1 Endocrinology
2 Eur J Radiol
5 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 Invest Radiol
2 J Nucl Med
10 J Urol
1 JAMA
2 Nat Rev Urol
1 Oncogene
3 PLoS One
2 Radiology
4 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Pathol

  1. VELLKY JE, Ricke EA, Huang W, Ricke WA, et al
    Expression and Localization of DDX3 in Prostate Cancer Progression and Metastasis.
    Am J Pathol. 2019 Mar 26. pii: S0002-9440(18)30965.
    PubMed     Text format     Abstract available


    BJU Int

  2. SARGOS P, Mottet N, Bellera C, Richaud P, et al
    Long-term androgen deprivation, with or without radiotherapy, in locally-advanced prostate cancer: updated results from a phase III randomized trial.
    BJU Int. 2019 Apr 4. doi: 10.1111/bju.14768.
    PubMed     Text format     Abstract available

  3. ALABOUSI M, Salameh JP, Gusenbauer K, Samoilov L, et al
    Biparametric versus Multiparametric Prostate MRI for the Detection of Prostate Cancer in Treatment-Naive Patients: A Diagnostic Test Accuracy Systematic Review and Meta-Analysis.
    BJU Int. 2019 Mar 31. doi: 10.1111/bju.14759.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. PARIKH NR, Huiza C, Patel JS, Tsai S, et al
    Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
    BMC Cancer. 2019;19:291.
    PubMed     Text format     Abstract available


    Cancer

  5. BARATA PC, Sartor AO
    Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or...
    Cancer. 2019 Apr 1. doi: 10.1002/cncr.32039.
    PubMed     Text format     Abstract available


    Cancer Lett

  6. SINGH V, Jaiswal PK, Ghosh I, Koul HK, et al
    The TLK1-Nek1 axis promotes Prostate Cancer progression.
    Cancer Lett. 2019 Mar 27. pii: S0304-3835(19)30197.
    PubMed     Text format     Abstract available

  7. XIE H, Liu T, Chen J, Yang Z, et al
    Activation of PSGR with beta-ionone suppresses prostate cancer progression by blocking androgen receptor nuclear translocation.
    Cancer Lett. 2019 Mar 27. pii: S0304-3835(19)30200.
    PubMed     Text format     Abstract available


    Endocrinology

  8. TAKAYAMA KI, Inoue S
    Response to Letter to the Editor: "Integrative Genomic Analysis of OCT1 Reveals Coordinated Regulation of Androgen Receptor in Advanced Prostate Cancer".
    Endocrinology. 2019 Apr 3. pii: 5425392. doi: 10.1210/en.2019-00207.
    PubMed     Text format    


    Eur J Radiol

  9. LI M, Huang Z, Yu H, Wang Y, et al
    Comparison of PET/MRI with multiparametric MRI in diagnosis of primary prostate cancer: A meta-analysis.
    Eur J Radiol. 2019;113:225-231.
    PubMed     Text format     Abstract available

  10. ONAY A, Vural M, Armutlu A, Ozel Yildiz S, et al
    Evaluation of the most optimal multiparametric magnetic resonance imaging sequence for determining pathological length of capsular contact.
    Eur J Radiol. 2019;112:192-199.
    PubMed     Text format     Abstract available


    Eur Urol

  11. CHEN WS, Aggarwal R, Zhang L, Zhao SG, et al
    Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30206.
    PubMed     Text format     Abstract available

  12. CARLSSON SV, Mansson M, Moss S, Kwiatkowski M, et al
    Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30196.
    PubMed     Text format     Abstract available

  13. LEIBOWITZ-AMIT R
    Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur
    Eur Urol. 2019 Mar 27. pii: S0302-2838(19)30199.
    PubMed     Text format    

  14. STOCKLE M
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    Eur Urol. 2019 Apr 1. pii: S0302-2838(19)30263.
    PubMed     Text format    

  15. ZHOU X, Han X
    Re: Thomas Van den Broeck, Roderick C.N. van den Bergh, Nicolas Arfi, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. In press. https://doi.org/10.1016/j.eu
    Eur Urol. 2019 Apr 1. pii: S0302-2838(19)30256.
    PubMed     Text format    


    Int J Cancer

  16. SCHMIDT JA, Fensom GK, Rinaldi S, Scalbert A, et al
    Patterns in metabolite profile are associated with risk of more aggressive prostate cancer: a prospective study of 3057 matched case-control sets from EPIC.
    Int J Cancer. 2019 Apr 5. doi: 10.1002/ijc.32314.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  17. PETERS M, van Son MJ, Moerland MA, Kerkmeijer LGW, et al
    MRI-guided ultrafocal HDR-brachytherapy for localised prostate cancer: median 4 year results of a feasibility study.
    Int J Radiat Oncol Biol Phys. 2019 Mar 26. pii: S0360-3016(19)30399.
    PubMed     Text format     Abstract available


    Invest Radiol

  18. MAAS MC, Litjens GJS, Wright AJ, Attenberger UI, et al
    A Single-Arm, Multicenter Validation Study of Prostate Cancer Localization and Aggressiveness With a Quantitative Multiparametric Magnetic Resonance Imaging Approach.
    Invest Radiol. 2019 Apr 3. doi: 10.1097/RLI.0000000000000558.
    PubMed     Text format     Abstract available


    J Nucl Med

  19. RAHBAR K, Hofman MS, Schrader AJ, Boegemann M, et al
    A Self-Fulfilling Prophecy: Comparing (177)Lu-PSMA Radioligand therapy in Taxane Naive vs Post-Taxane metastasized Prostate Cancer Patients?
    J Nucl Med. 2019 Mar 29. pii: jnumed.119.228742. doi: 10.2967/jnumed.119.228742.
    PubMed     Text format    

  20. JADVAR H, Velez E, Desai B, Ji L, et al
    Prediction of time to hormonal treatment failure in metastatic castrate-sensitive prostate cancer with (18)F-FDG PET/CT.
    J Nucl Med. 2019 Mar 29. pii: jnumed.118.223263. doi: 10.2967/jnumed.118.223263.
    PubMed     Text format     Abstract available


    J Urol

  21. JIANG P, Liss MA, Szabo RJ
    Targeted Antimicrobial Prophylaxis Does Not Always Prevent Sepsis after Transrectal Prostate Biopsy.
    J Urol. 2018;200:361-368.
    PubMed     Text format     Abstract available

  22. GUO DP, Thomas IC, Mittakanti HR, Shelton JB, et al
    The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration.
    J Urol. 2018;200:541-548.
    PubMed     Text format     Abstract available

  23. BABALOLA O, Lee TJ, Viviano CJ
    Prostate Ablation Using High Intensity Focused Ultrasound: A Literature Review of the Potential Role for Patient Preference Information.
    J Urol. 2018;200:512-519.
    PubMed     Text format     Abstract available

  24. XU AJ, Taksler GB, Llukani E, Lepor H, et al
    Long-Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15-Year Longitudinal Study.
    J Urol. 2018;200:626-632.
    PubMed     Text format     Abstract available

  25. GAFFNEY C, Golan R, Cantu MD, Scognamiglio T, et al
    The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
    J Urol. 2019 Feb 12:101097JU0000000000000170. doi: 10.1097/JU.0000000000000170.
    PubMed     Text format     Abstract available

  26. JAMASPISHVILI T, Patel P, Niu Y, Vidotto T, et al
    MP28-02 QUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available

  27. SHOAG J, Liu D, Ma X, Oromendia C, et al
    MP68-12 IMPACT OF SPOP MUTATION ON PROSTATE CANCER PROGNOSIS.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available

  28. SANDHU HS, Mulholland DJ
    MP68-11 IDENTIFICATION OF INTERMEDIATE CELL POPULATIONS DURING TREATMENT INDUCED LINEAGE CONVERSION TO NEUROENDOCRINE PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available

  29. VELLKY J, Ricke W
    MP68-13 DDX3-MEDIATED TRANSLATIONAL REGULATION OF ANDROGEN RECEPTOR IN PROSTATE CANCER PROGRESSION.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available

  30. FAISAL F, Alshalalfa M, Davicioni E, Karnes RJ, et al
    MP68-10 HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION.
    J Urol. 2019;201.
    PubMed     Text format     Abstract available


    JAMA

  31. WYNER LM
    Artist, Rediscovered: Images and Ethics of Early Prostate Cancer Screening.
    JAMA. 2019;321:1236-1238.
    PubMed     Text format    


    Nat Rev Urol

  32. LITWIN MS
    The resilience of men: quality of life after prostate cancer.
    Nat Rev Urol. 2019 Apr 3. pii: 10.1038/s41585-019-0176.
    PubMed     Text format    

  33. MEYER AR, Gorin MA
    First point-of-care PSA test for prostate cancer detection.
    Nat Rev Urol. 2019 Apr 4. pii: 10.1038/s41585-019-0179.
    PubMed     Text format    


    Oncogene

  34. IPPOLITO L, Morandi A, Taddei ML, Parri M, et al
    Cancer-associated fibroblasts promote prostate cancer malignancy via metabolic rewiring and mitochondrial transfer.
    Oncogene. 2019 Apr 1. pii: 10.1038/s41388-019-0805.
    PubMed     Text format     Abstract available


    PLoS One

  35. SEKHAR KR, Wang J, Freeman ML, Kirschner AN, et al
    Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.
    PLoS One. 2019;14:e0214670.
    PubMed     Text format     Abstract available

  36. BALLARINI NM, Rosenkranz GK, Jaki T, Konig F, et al
    Subgroup identification in clinical trials via the predicted individual treatment effect.
    PLoS One. 2018;13:e0205971.
    PubMed     Text format     Abstract available

  37. MARZORATI C, Monzani D, Mazzocco K, Pavan F, et al
    Predicting trajectories of recovery in prostate cancer patients undergone Robot-Assisted Radical Prostatectomy (RARP).
    PLoS One. 2019;14:e0214682.
    PubMed     Text format     Abstract available


    Radiology

  38. JOHNSTON EW, Bonet-Carne E, Ferizi U, Yvernault B, et al
    VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient.
    Radiology. 2019 Apr 2:181749. doi: 10.1148/radiol.2019181749.
    PubMed     Text format     Abstract available

  39. SIGMUND EE, Rosenkrantz AB
    Diffusion-weighted Imaging of Prostate Cancer: Revisiting Occam's Razor.
    Radiology. 2019 Apr 2:190371. doi: 10.1148/radiol.2019190371.
    PubMed     Text format    


    Urology

  40. BORETA L, Gadzinski AJ, Wu SY, Xu M, et al
    Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy.
    Urology. 2019 Mar 27. pii: S0090-4295(19)30262.
    PubMed     Text format     Abstract available

  41. BRYK DJ, Angermeier KW, Klein EA
    A Case of Metastatic Prostate Cancer to the Urethra that Resolved after Androgen Deprivation Therapy.
    Urology. 2019 Mar 29. pii: S0090-4295(19)30323.
    PubMed     Text format     Abstract available

  42. FAM MM, Yabes JG, Macleod LC, Bandari J, et al
    Increasing Utilization of Multi-Parametric Magnetic Resonance Imaging in Prostate Cancer Active Surveillance.
    Urology. 2019 Mar 30. pii: S0090-4295(19)30321.
    PubMed     Text format     Abstract available

  43. ROCCO B, Sighinolfi MC, Sandri M, Eissa A, et al
    Is Extraprostatic Extension of Cancer Predictable? A Review of Predictive Tools and an External Validation based on a Large and a Single Center Cohort of Prostate Cancer Patients.
    Urology. 2019 Mar 27. pii: S0090-4295(19)30316.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: